Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Zentalis Pharmaceuticals Emerges with $85M Round for Cancer Drugs

Cancer drug developer Zentalis Pharmaceuticals recently surfaced with an $85 million round. The funding was a series C financing, an unusually late point for a drugmaker to make its public debut.

Evofem’s Gel Shows Promise Preventing Some STDs

Evofem Biosciences’ gel in midstage clinical trials reduced the risk of chlamydia and gonorrhea infections compared to a placebo.

Cancer Drug Developer Synthorx Acquired for $2.5 Billion

French pharmaceutical Sanofi will pay $2.5 billion to buy Synthorx, a San Diego biotech that expanded the genetic alphabet in a quest to treat cancer.

Presidium Health's Concierge Care Takes On Tough Cases

MEDICINE: Focus Put on Population of Frequent ER Users

Just 5% of patients account for roughly half of the nation’s health care spending. These “super users” cycle through emergency rooms.

Tease photo

Neurocrine Pays $50 Million for Epilepsy Drug Candidate

PHARMA: Xenon Could Receive up to $1.7 Billion In Milestone Payments

Neurocrine Biosciences has plunked down $50 million upfront for a potential epilepsy treatment, the San Diego company’s second major licensing deal this year.

Tease photo

Potential $31 Million Deal Shows Canale’s Work Paid Off

UDG Aims to Expand Footprint, Especially in West Coast

Carin Canale-Theakston founded Canale Communications. Her twin goals: build the largest life sciences communications firm on the West Coast.

Tease photo

Evofem’s Gel Lessens Risk of Chlamydia, Gonorrhea in Clinical Trial

Evofem Biosciences’ gel in mid-stage clinical trials reduced the risk of chlamydia and gonorrhea infections compared to a placebo, the San Diego company reported Dec. 2.

Phoenix Molecular’s Seed Funding Reaches $12 Million

Co. Targets RSK2 Enzyme Often Found in Breast Cancers

Phoenix Molecular Designs is attacking advanced breast cancer in a new way — and with added funding.

Avidity Gets $100M For Research Into Muscle Disorders

More Than a Dozen Entities Invest in Preclinical Programs

Avidity Biosciences recently was awarded a $100 million series C round.

Truvian Seeks to Decentralize Blood Testing

BIOTECH: Co. Aims for Transparency in Each Step

Truvian Sciences wants to run a battery of tests on only drops of blood. Its mobile lab is designed to return answers in 20 minutes.

More stories >>